Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Description:

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. – PowerPoint PPT presentation

Number of Views:855

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019


1
Idiopathic Thrombocytopenic Purpura (ITP)
Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
  • Aarkstore Enterprise specialize in providing
    online market business information on market
    research reports, books, magazines, conference
    booking at competitive prices, and strive to
    provide excellent and innovative service to our
    customers.

2
Idiopathic Thrombocytopenic Purpura (ITP)
Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
  • Date 29 February 2012
  • Pages 63
  • SummaryCompany, the industry analysis
    specialist, has released its new report,
    Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics - Pipeline Assessment and Market
    Forecasts to 2019. The report is an essential
    source of information and analysis on the global
    Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market. The report identifies the
    key trends shaping and driving the global
    Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market. The report also provides
    insights on the prevalent competitive landscape
    and the emerging players expected to
    significantly alter the market positioning of the
    current market leaders. Most importantly, the
    report provides valuable insights on the pipeline
    products within the global Idiopathic
    Thrombocytopenic Purpura (ITP) Therapeutics
    sector. This report is built using data and
    information sourced from proprietary databases,
    primary and secondary research and in-house
    analysis by Company team of industry
    experts.ScopeThe report provides information
    on the key drivers and challenges of the
    Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market. Its scope includes - -
    Annualized seven key markets (US, France,
    Germany, Italy, Spain, UK and Japan) Idiopathic
    Thrombocytopenic Purpura (ITP) Therapeutics
    market revenues data from 2006 to 2011, forecast
    for eight years to 2019. - Pipeline analysis
    data providing a split across the different
    phases, mechanisms of action being developed and
    emerging trends by seven key markets. Pipeline
    candidates fall under major therapeutic
    classes.- Analysis of the current and future
    competition in the seven key countries Idiopathic
    Thrombocytopenic Purpura (ITP) Therapeutics
    market. - Insightful review of the key industry
    drivers, restraints and challenges. Each trend is
    independently researched to provide a qualitative
    analysis of its implications. - Key topics
    covered include strategic competitor assessment,
    market characterization, unmet needs and the
    implications for the Idiopathic Thrombocytopenic
    Purpura (ITP) Therapeutics market.- Analysis of
    key recent licensing and partnership agreements
    in Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market

3
Clostridium difficile Infection (CDI)
Therapeutics - Pipeline Assessment and Market
Forecasts to 2019
  • Reasons to buyThe report will enhance your
    decision making capability. It will allow you to
    - - Develop and design your in-licensing and
    out-licensing strategies through a review of
    pipeline products and technologies and by
    identifying the companies with the most robust
    pipeline. - Develop business strategies by
    understanding the trends shaping and driving the
    global Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market. - Drive revenues by
    understanding the key trends, innovative products
    and technologies, market segments and companies
    likely to impact the global Idiopathic
    Thrombocytopenic Purpura (ITP) Therapeutics
    market in future. - Formulate effective sales
    and marketing strategies by understanding the
    competitive landscape and by analyzing the
    performance of various competitors. - Identify
    emerging players with potentially strong product
    portfolios and create effective
    counter-strategies to gain a competitive
    advantage. - Organize your sales and marketing
    efforts by identifying the market categories and
    segments that present maximum opportunities for
    consolidations, investments and strategic
    partnerships. - What the next big thing in the
    global Idiopathic Thrombocytopenic Purpura (ITP)
    Therapeutics market landscape? Identify,
    understand and capitalize.

4
1.1 List of Tables 51.2 List of Figures 62
Idiopathic Thrombocytopenic Purpura (ITP)
Therapeutics - Introduction 72.1 Overview 72.2
Classification of Idiopathic Thrombocytopenic
Purpura 72.3 Pathophysiology of Chronic
Idiopathic Thrombocytopenic Purpura 82.4
Epidemiology 92.5 Clinical Symptoms 92.6
Diagnosis and Management of Idiopathic
Thrombocytopenic Purpura 92.7 Treatment of
Idiopathic Thrombocytopenic Purpura 112.8
GlobalData Pipeline Report Guidance 123
Idiopathic Thrombocytopenic Purpura Therapeutics
- Market Characterization 133.1 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - Global 133.2 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - Global 143.3 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - the US 153.4 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - the US 163.5 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - the UK 173.6 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - the UK 183.7 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - France 193.8 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - France 203.9 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - Germany 213.10 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - Germany 223.11 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - Italy 233.12 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - Italy 243.13 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - Spain 253.14 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - Spain 263.15 Idiopathic
Thrombocytopenic Purpura Therapeutics Market Size
(2006-2011) - Japan 273.16 Idiopathic
Thrombocytopenic Purpura Therapeutics Market
Forecast (2011-2019) - Japan 283.16.1 Drivers
for the Idiopathic Thrombocytopenic Purpura
Therapeutics Market 293.16.2 Barriers for the
Idiopathic Thrombocytopenic Purpura Therapeutics
Market 293.17 Key Events Impacting the Future
Market 303.18 Opportunity and Unmet Need 313.19
Key Takeaway 32
5

4 Idiopathic Thrombocytopenic Purpura
Therapeutics Market - Competitive Assessment
334.1 Overview 334.2 Strategic Competitor
Assessment 334.3 Product Profiles for the Major
Marketed Products in the Idiopathic
Thrombocytopenic Purpura Therapeutics Market
344.3.1 Nplate (romiplostim) 344.3.2
Promacta/Revolade (eltrombopag) 344.4 Key
Takeaway 355 Idiopathic Thrombocytopenic Purpura
Therapeutics Market - Pipeline Assessment 365.1
Overview 365.1.1 Strategic Pipeline Assessment
365.2 Idiopathic Thrombocytopenic Purpura
Therapeutics Pipeline Analysis - Pipeline by
Clinical Phases of Development 365.2.1 ITP
Therapeutics - Phase III Clinical Pipeline
365.2.2 Idiopathic Thrombocytopenic Purpura
Therapeutics - Phase II Clinical Pipeline
375.2.3 Idiopathic Thrombocytopenic Purpura
Therapeutics - Phase I/II Clinical Pipeline
375.2.4 Idiopathic Thrombocytopenic Purpura
Therapeutics - Pre-Clinical Pipeline 375.3
Idiopathic Thrombocytopenic Purpura Therapeutics
Market - Clinical Pipeline by Mechanism of Action
385.4 Idiopathic Thrombocytopenic Purpura
Technology Trends Analytical Framework 395.5
Molecule Profile for Late-Stage Drugs under
Clinical Development 405.5.1 IGIV3I 10 Grifols
405.5.2 Mabthera (rituximab) 415.6 Key Takeaway
416 Idiopathic Thrombocytopenic Purpura
Therapeutics - Clinical Trials Mapping 426.1
Clinical Trials by Country 426.2 Clinical Trials
by Phase 436.3 Clinical Trials by Trial Status
446.4 Overall Sponsors 456.5 Prominent Sponsors
466.6 Top Companies Participating in Idiopathic
Thrombocytopenic Purpura Therapeutics Clinical
Trials 47
6

7 Idiopathic Thrombocytopenic Purpura
Therapeutics - Strategic Assessment 487.1 Future
Market Competition Scenario 488 Idiopathic
Thrombocytopenic Purpura Therapeutics - Future
Players 498.1 Introduction 498.2 Company
Profiles 508.2.1 F. Hoffmann-La Roche 508.2.2
Grifols Biologicals Inc. 518.2.3 Amgen Inc.
518.2.4 GlaxoSmithKline plc 538.2.5 Other
Companies in the Idiopathic Thrombocytopenic
Purpura Therapeutics Market, 2011 559 Idiopathic
Thrombocytopenic Purpura Therapeutics - Licensing
and Partnership Deals 5610 Idiopathic
Thrombocytopenic Purpura Therapeutics - Appendix
5710.1 Definitions 5710.2 Acronyms 5710.3
Research Methodology 5810.3.1 Coverage 5810.3.2
Secondary Research 5810.3.3 Forecasting
5910.3.4 Primary Research 6110.3.5 Expert Panel
Validation 6210.4 Contact Us 6210.5 Disclaimer
6210.6 Bibliography 62 
7
  • For more information, please visit
  • http//www.aarkstore.com/reports/Idiopathic-Thromb
    ocytopenic-Purpura-ITP-Therapeutics-Pipeline-Asses
    sment-and-Market-Forecasts-to-2019-198832.htmlOr
    email us at contact_at_aarkstore.com or call
    919272852585
  • Related Reports
  • Vemurafenib - Comprehensive patent
    search Colesevelam - Comprehensive patent
    search Rifaximin - Comprehensive patent
    search Nevirapine - Comprehensive patent
    search Liraglutide - Comprehensive patent
    search Vilazodone - Comprehensive patent
    search Hexylaminolevulinic Acid - Comprehensive
    patent search Treprostinil - Comprehensive
    patent search Patient Adherence, Communication
    and Engagement (PACE) - Increased Investment and
    Adoption of New Digital Tools Enable Key
    Stakeholder Collaborations and Encourage
    Compliance Express Scripts, Inc.
    Pharmaceuticals and Healthcare Company Profile,
    SWOT and Financial Report

8
Contact Us
  • Aarkstore Enterprise
  • Tel 912227453309
  • Mobile No08149852585
  • Email contact_at_aarkstore.com
  • Website http//www.aarkstore.com
  • Blog http//www.emarketreports.com
  • http//teju-aarkstoreenterprise.blogspot.in
  • Follow us on twitter http//twitter.com/aarkstore
    dotcom
  • http//in.linkedin.com/in/aarkstore
  • http//www.facebook.com/aarkstoreenterprise
About PowerShow.com